Cyclophosphamide or plerixafor and G-CSF for stem cell mobilization: initial cost comparison analysis
M. Jagasia,S. Pickard,H. Chen,S. Dixon,B. Savani
DOI: https://doi.org/10.1016/j.bbmt.2009.12.152
2010-01-01
Biology of Blood and Marrow Transplantation
Abstract:Autologous SCM is usually done using myelosuppressive chemotherapy plus G-CSF (G), which is considered safe and effective, but exposes patients (pts) to risks and side effects. To better understand the comparative effectiveness of standard and newer treatments for SCM, the aims of study were: (1) clinical outcomes and cost consequences of cyclophophamide (CY) plus G SCM (2) to compare outcomes of CY+G to a clinical trial of plerixafor (P)+G. A retrospective study was conducted in all patients undergoing first SCM from 1/04 to 3/08 (N=241) with CY (3 gm/m2) and G (10 mcg/kg started day after CY for 10 days with a planned first day of collection on day 11) and pheresis initiated when peripheral blood had >15 CD34+ cells/uL. Positive clinical outcome (PCO) was defined as >2×106 CD34+ cells/kg collected on planned day of collection in 1 or 2 apheresis without a prior negative event that led to additional clinic/inpatient evaluation. The cost of drugs, pheresis, product processing, and clinical events, were reported based on Medicare part B physician, laboratory, and ancillary fee schedule. Data on pts undergoing SCM with P+G were obtained from a published clinical trial in pts with myeloma (MM) and lymphoma (L) undergoing first SCM that used G (10 mcg/kg without dose escalation) and non-mobilizers had a maximum of 4 days of P. Among CY+G pts, 141 (61%) were males; 121 (50%) had MM, 115 (48%) had L (5-other diagnoses); 61 (25%) pts. had prior radiation. PCO was seen in 48 (20%) pts., 23% of MM and 15.7% of L pts. Mean total cost of CY+G SCM was $10,732 (range, 6988-30827). PCO was associated with a lower cost than non-PCO in the overall group, (mean, $10,371 vs. $12,870, P=0.001), in MM pts. (mean, $10,511 vs. $12,152, P=0.026), and in L pts (mean, $10,133 vs. $13,627, P=0.006). Assuming a similar distribution of PCO in 100 pt. with MM and L, the projected per pt cost of SCM would be $11,774 and $13,067 (mean, $12,421) with CY+G. Projected costs of SCM using P+G for 100 pts. with MM and L were $12,852 and $8986 (mean, $10,919). SCM with CY+G was associated with a lower rate of PCO and higher cost than P+G. This comparision is limited by different sources of patient data, only the CY+G data was “real world”, and only product-related costs were examined. This study represents an important initial step towards informing cancer management based on a profile of outcomes that compare relevant therapeutic alternatives.